MedTrace Logo

Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane

NCT00936026 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2011-02-08

No results posted yet for this study

Summary

Primary:

To assess the effects of CYP2B6 inhibition by repeated dose Clopidogrel (75 mg/day) co-administration on the single-dose pharmacokinetics of Neramexane

Secondary:

To assess safety and tolerability of Neramexane single dose treatment alone and co-administration of a Neramexane single-dose with a Clopidogrel repeated dose treatment

Conditions

  • Healthy Subjects

Interventions

DRUG

Neramexane

Drug-Drug Interaction Study

Sponsors & Collaborators

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Study Design

Masking
NONE

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936026 on ClinicalTrials.gov